Lv1
40 积分 2024-12-15 加入
Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape
3个月前
已完结
3085P PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients
3个月前
已关闭
皖公网安备34019202002308
